Compare Stocks: ABCM, INSM, EXEL, and ASND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCM Abcam	$23.99	$23.88	$12.48 ▼ $25.32	$5.50B	0.86	3.08 million shs	N/A
ASND Ascendis Pharma A/S	$229.23 +2.9%	$246.62	$186.05 ▼ $282.15	$13.89B	0.38	969,992 shs	815,738 shs
EXEL Exelixis	$59.86 +1.4%	$56.26	$33.76 ▼ $61.14	$14.62B	0.47	2.22 million shs	2.67 million shs
INSM Insmed	$100.60 +0.1%	$120.20	$90.39 ▼ $212.75	$21.94B	0.83	2.74 million shs	2.47 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCM Abcam	0.00%	0.00%	0.00%	0.00%	0.00%
ASND Ascendis Pharma A/S	+2.94%	+0.60%	-12.11%	-15.24%	+9.09%
EXEL Exelixis	+1.42%	+2.52%	+2.62%	+5.95%	+54.92%
INSM Insmed	+0.12%	-9.47%	-21.89%	-12.98%	-37.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCM Abcam	$23.99	$23.88	$12.48 ▼ $25.32	$5.50B	0.86	3.08 million shs	N/A
ASND Ascendis Pharma A/S	$229.23 +2.9%	$246.62	$186.05 ▼ $282.15	$13.89B	0.38	969,992 shs	815,738 shs
EXEL Exelixis	$59.86 +1.4%	$56.26	$33.76 ▼ $61.14	$14.62B	0.47	2.22 million shs	2.67 million shs
INSM Insmed	$100.60 +0.1%	$120.20	$90.39 ▼ $212.75	$21.94B	0.83	2.74 million shs	2.47 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCM Abcam	0.00%	0.00%	0.00%	0.00%	0.00%
ASND Ascendis Pharma A/S	+2.94%	+0.60%	-12.11%	-15.24%	+9.09%
EXEL Exelixis	+1.42%	+2.52%	+2.62%	+5.95%	+54.92%
INSM Insmed	+0.12%	-9.47%	-21.89%	-12.98%	-37.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCM Abcam	0.00	N/A	N/A	N/A
ASND Ascendis Pharma A/S	3.00	Buy	$313.21	36.64% Upside
EXEL Exelixis	2.35	Hold	$50.79	-15.16% Downside
INSM Insmed	2.96	Moderate Buy	$200.57	99.37% Upside

Current Analyst Ratings Breakdown

Latest ABCM, INSM, EXEL, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	EXEL Exelixis	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$51.00
10/8/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (A-) ➝ Buy (A)
10/8/2026	INSM Insmed	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/8/2026	EXEL Exelixis	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$46.00 ➝ $45.00
10/7/2026	EXEL Exelixis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$52.00 ➝ $54.00
10/6/2026	INSM Insmed	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/30/2026	INSM Insmed	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$237.00 ➝ $207.00
9/25/2026	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$300.00
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/24/2026	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$188.00
9/16/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$344.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCM Abcam	$379.70M	14.49	$0.60 per share	40.17	$3.92 per share	6.12
ASND Ascendis Pharma A/S	$814.57M	17.55	N/A	N/A	($2.97) per share	-77.18
EXEL Exelixis	$2.32B	6.39	$3.07 per share	19.50	$8.06 per share	7.43
INSM Insmed	$1.14B	19.31	N/A	N/A	$3.46 per share	29.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCM Abcam	-$10.51M	N/A	N/A	42.09	2.19	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	-$258M	$12.89	17.78	25.67	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.82	16.09	1.76	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	104.79	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)

Latest ABCM, INSM, EXEL, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	EXEL Exelixis	$0.8780	N/A	N/A	N/A	$646.95 million	N/A
10/29/2026	Q3 2026	INSM Insmed	-$0.3981	N/A	N/A	N/A	$499.31 million	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCM Abcam	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCM Abcam	N/A	1.35	1.00
ASND Ascendis Pharma A/S	0.27	2.99	2.32
EXEL Exelixis	N/A	3.46	3.38
INSM Insmed	0.74	3.72	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCM Abcam	90.45%
ASND Ascendis Pharma A/S	N/A
EXEL Exelixis	85.27%
INSM Insmed	N/A

Insider Ownership

Company	Insider Ownership
ABCM Abcam	6.73%
ASND Ascendis Pharma A/S	40.00%
EXEL Exelixis	2.60%
INSM Insmed	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCM Abcam	1,760	229.27 million	213.84 million	No Data
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable

ABCM, INSM, EXEL, and ASND Headlines

Recent News About These Companies

Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative?

October 8 at 10:04 PM | uk.finance.yahoo.com

Insmed reaffirmed guidance. Insmed stock fell 4.71 percent

October 8 at 10:04 PM | ad-hoc-news.deA

BMO Capital Sticks to Its Buy Rating for Insmed (INSM)

October 7 at 11:05 PM | theglobeandmail.com

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

October 7 at 1:03 PM | biopharmadive.comB

Insmed stock falls 6.56 percent after CFO transition

October 6, 2026 | ad-hoc-news.deA

Insmed CFO Sara Bonstein To Step Down As Company Reaffirms 2026 Guidance

October 6, 2026 | pulse2.comP

INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

October 6, 2026 | zacks.com

Insmed CFO Sara Bonstein To Step Down

October 5, 2026 | rttnews.com

Insmed Incorporated Reaffirms Earnings Guidance for the Full-Year 2026

October 5, 2026 | marketscreener.comM

Insmed Chief Financial Officer Sara Bonstein to Step Down

October 5, 2026 | finance.yahoo.com

Insmed Incorporated Announces Sara Bonstein Steps Down as Chief Financial Officer, Effective October 30, 2026

October 5, 2026 | marketscreener.comM

Insmed stock falls as CFO Sara Bonstein to step down

October 5, 2026 | uk.finance.yahoo.com

Insmed CFO Bonstein to Step Down; Backs FY Guidance

October 5, 2026 | marketwatch.com

Insmed (NASDAQ:INSM) Shares Gap Down - What's Next?

October 5, 2026 | marketbeat.com

Insmed Announces CFO Transition

October 5, 2026 | prnewswire.com

Ty Pennington Admits He ‘Never Thought’ He’d Be Living with His Mom Again as He Becomes Her Caretaker (Exclusive)

October 2, 2026 | msn.com

Contrasting Agios Pharmaceuticals (NASDAQ:AGIO) & Insmed (NASDAQ:INSM)

September 29, 2026 | americanbankingnews.com

3 Healthcare Stocks Showing Why the Sector Still Has Momentum (INSM)

...

September 28, 2026 | marketbeat.com

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

September 28, 2026 | insidermonkey.com

Mizuho Securities Sticks to Its Buy Rating for Insmed (INSM)

September 25, 2026 | theglobeandmail.com

Insmed (NASDAQ:INSM) Stock Rating Upgraded by The Goldman Sachs Group

September 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABCM, INSM, EXEL, and ASND Company Descriptions

Abcam NASDAQ:ABCM

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Ascendis Pharma A/S NASDAQ:ASND

$229.23 +6.54 (+2.94%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$229.14 -0.09 (-0.04%)

As of 10/9/2026 07:30 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis NASDAQ:EXEL

$59.86 +0.84 (+1.42%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$60.06 +0.20 (+0.33%)

As of 10/9/2026 07:57 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Insmed NASDAQ:INSM

$100.60 +0.12 (+0.12%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$101.12 +0.52 (+0.52%)

As of 10/9/2026 07:47 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCM, INSM, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCM, INSM, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCM, INSM, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABCM, INSM, EXEL, and ASND Company Descriptions

Abcam NASDAQ:ABCM

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Insmed NASDAQ:INSM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCM, INSM, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCM, INSM, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCM, INSM, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABCM, INSM, EXEL, and ASND Company Descriptions

Abcam NASDAQ:ABCM

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Insmed NASDAQ:INSM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools